N4 Pharma (N4P) Competitors GBX 0.50 +0.05 (+11.11%) As of 08/1/2025 12:04 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsBuy This Stock N4P vs. HELD, HLN, BXP, HIK, HCM, INDV, AMYT, AGY, APH, and ANCRShould you be buying N4 Pharma stock or one of its competitors? The main competitors of N4 Pharma include Hellenic Dynamics (HELD), Haleon (HLN), Beximco Pharmaceuticals (BXP), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Allergy Therapeutics (AGY), Alliance Pharma (APH), and Animalcare Group (ANCR). These companies are all part of the "drug manufacturers - specialty & generic" industry. N4 Pharma vs. Its Competitors Hellenic Dynamics Haleon Beximco Pharmaceuticals Hikma Pharmaceuticals HUTCHMED Indivior Amryt Pharma Allergy Therapeutics Alliance Pharma Animalcare Group Hellenic Dynamics (LON:HELD) and N4 Pharma (LON:N4P) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership. Does the media favor HELD or N4P? In the previous week, Hellenic Dynamics' average media sentiment score of 0.00 equaled N4 Pharma'saverage media sentiment score. Company Overall Sentiment Hellenic Dynamics Neutral N4 Pharma Neutral Is HELD or N4P more profitable? Hellenic Dynamics has a net margin of 0.00% compared to N4 Pharma's net margin of -18,399.86%. N4 Pharma's return on equity of -90.68% beat Hellenic Dynamics' return on equity.Company Net Margins Return on Equity Return on Assets Hellenic DynamicsN/A -364.21% N/A N4 Pharma -18,399.86%-90.68%-56.00% Which has preferable valuation and earnings, HELD or N4P? N4 Pharma has higher revenue and earnings than Hellenic Dynamics. N4 Pharma is trading at a lower price-to-earnings ratio than Hellenic Dynamics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHellenic DynamicsN/AN/A-£5.22M-£3.550.00N4 Pharma£8.84K243.55-£1.63M-£0.35-1.44 Do insiders and institutionals hold more shares of HELD or N4P? 0.1% of Hellenic Dynamics shares are owned by institutional investors. 72.9% of Hellenic Dynamics shares are owned by company insiders. Comparatively, 18.0% of N4 Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryHellenic Dynamics beats N4 Pharma on 5 of the 9 factors compared between the two stocks. Get N4 Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for N4P and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding N4P and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart N4P vs. The Competition Export to ExcelMetricN4 PharmaDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£2.15M£2.13B£5.49B£3.03BDividend Yield3.12%2.92%4.73%5.02%P/E Ratio-1.444.2628.78176.75Price / Sales243.55677.32372.20264,362.45Price / Cash2.2510.3535.4527.97Price / Book1.1210.908.274.53Net Income-£1.63M£21.15B£3.25B£5.90B7 Day Performance25.00%0.37%-3.70%12.58%1 Month Performance25.00%4.48%4.34%6.10%1 Year Performance-16.67%2.65%25.90%71.60% N4 Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)N4PN4 PharmaN/AGBX 0.50+11.1%N/A-16.7%£2.15M£8.84K-1.445Gap UpHELDHellenic DynamicsN/AGBX 0.01flatN/AN/A£14KN/A0.00N/AHLNHaleon1.207 of 5 starsGBX 365.81+0.2%GBX 457+24.9%+2.2%£33.02B£11.07B30.7725,408News CoverageEarnings ReportAnalyst ForecastBXPBeximco PharmaceuticalsN/AGBX 39.10-1.0%N/A+1.3%£26.65B£7.08T4.205,500HIKHikma Pharmaceuticals3.3997 of 5 starsGBX 2,004-1.2%GBX 2,560+27.7%+1.7%£5.56B£3.74B19.669,100HCMHUTCHMEDN/AGBX 258-3.0%N/A-9.6%£2.80B£771.01M-65.851,760INDVIndivior2.965 of 5 starsGBX 1,238+1.6%GBX 1,650+33.3%+17.1%£1.93B£1.40B-1,026.481,000News CoverageGap UpHigh Trading VolumeAMYTAmryt PharmaN/AN/AN/AN/A£457.11M£210.24M-4.33290Gap DownAGYAllergy TherapeuticsN/AGBX 8-1.2%N/A+60.0%£393.21M£72.18M-7.71612Gap UpHigh Trading VolumeAPHAlliance Pharma2.033 of 5 starsGBX 64.70flatGBX 6,250+9,560.0%N/A£350.32M£183.50M-10.4391,000ANCRAnimalcare GroupN/AGBX 261.13-0.7%N/A-2.6%£179.03M£84.90M4.87220Gap Down Related Companies and Tools Related Companies Hellenic Dynamics Alternatives Haleon Alternatives Beximco Pharmaceuticals Alternatives Hikma Pharmaceuticals Alternatives HUTCHMED Alternatives Indivior Alternatives Amryt Pharma Alternatives Allergy Therapeutics Alternatives Alliance Pharma Alternatives Animalcare Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:N4P) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding N4 Pharma Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share N4 Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
